Vascular degeneration in Parkinson’s disease
Objective: To determine the role vascular degeneration in human Parkinson's disease (PD). Background: We have previously reported endothelial degeneration in the PD. Current study examined…Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia
Objective: To evaluate the role of the atypical vesicular glutamate transporter 3 (VGLUT3) and the vesicular acetylcholine transporter (VAChT) in L-DOPA-induced dyskinesia. Background: Parkinson's disease…Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease
Objective: To assess if a microglial modulator, Glatiramer Acetate (GA), can restore loss of striatal dopamine (DA) and behavioral deficits following progressive 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP)…Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease
Objective: To Evaluate:prepared a MPTP/p induced mouse subacute model of PD, and explore the modulatory effect of H2S on monoamine and amino acid neurotransmitters in…The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease
Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…
- « Previous Page
- 1
- …
- 7
- 8
- 9